1-(3-chloropropyl)-4-(4-fluorophenyl)piperazine | 81514-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-chloropropyl)-4-(4-fluorophenyl)piperazine
• 英文别名: 1-[4-(4-fluorophenyl)piperazin-1-yl]-3-chloropropane
• CAS: 81514-10-5
• 化学式: C₁₃H₁₈ClFN₂
• 分子量: 256.751
• InChiKey: BKDWMIXCARHYKX-UHFFFAOYSA-N

物化性质

• 沸点：
  368.3±42.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-chloropropyl)-4-(4-fluorophenyl)piperazine 以71%的产率得到1-[2-(1,3,4-oxadiazol-2-yl)-phenoxy]-3-[4-(4-fluorophenyl)-piperazin-1-yl]-propane
  参考文献：
  名称：

  Phenylpiperazine derivatives of hetarylphenols and hetarylanilines,

  摘要：

  新型苯基哌嗪基丙烷和丁烷衍生物，其为杂环酚和杂环苯胺的化合物，化学式为##STR1##其中R.sup.1为氢或1至4个碳原子的烷基，R.sup.2为氢、卤素、1至4个碳原子的烷基或烷氧基，其中烷基为1至3个碳原子，苯环可以被R.sup.2单取代或双取代，X为氧或NH基团，杂环结构Het.为1,3,4-噁二唑基、三唑基、咪唑基或吡唑基，以及它们与酸形成的生理耐受性盐，其制备方法，以及含有这些化合物并表现出主要镇静、神经阻滞和降压特性的药物配方。

  公开号：

  US04619929A1
• 作为产物：
  描述：

  1-(4-氟苯基)哌嗪 在 氯化亚砜 、 potassium carbonate 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 32.0h， 生成 1-(3-chloropropyl)-4-(4-fluorophenyl)piperazine
  参考文献：
  名称：

  3- [2- [4-(4-Fluorobenzoyl)piperidin- 1-yl]ethyl] -5,6,7,8-tetrahydro-4(3H)-quinazolinones: serotonin 5-HT2A receptor antagonists endowed with potent central action

  摘要：

  A series of 5,6,7,8-tetrahydro-4(3H)-quinazolinones substituted at the 3-position with 4-benzoyl-1-ethylpiperidine, 4-(4-fluorobenzoyl)-1-ethylpiperidine, 4-[bis-(4-fluorophenyl)methylene]-1-ethylpiperidine, or 4-(4-fluorophenyl)-1-propylpiperazine have been prepared and evaluated in binding assays to determine their affinity at serotonin 5-HT2A receptors as well as in a functional test, ie, wet dog shakes (WDS) induced by L-5-hydroxytryptophan (L-5-HTP), a behavioural response which is mediated by stimulation of 5-HT receptors. Among the compounds prepared. 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone (10b) and 2-methyl-3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone (10b) proved to be the most potent 5-HT,, receptor antagonists. In binding assays, the two compounds displayed similar affinity for 5-HT, receptors in the nanomolar range to ketanserin and ritanserin. In the WDS test, they were even more potent than ketanserin and ritanserin. Compound 10b, which was found to possess the highest potency and duration of action in the WDS test, was chosen for a preliminary evaluation of its ability to inhibit ethanol intake in rats, a response linked to blockade of the central 5-HT2A, receptors. This compound significantly reduced ethanol intake in rats from the first day of treatment. The results of the present study indicate that 10b is a potent centrally acting antagonist at 5-HT2A receptors.

  DOI：

  10.1016/s0223-5234(97)83291-6

文献信息

• Design, synthesis, and biological evaluation of arylpiperazine–benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities
  作者：Suresh Paudel、Srijan Acharya、Kyeong-Man Kim、Seung Hoon Cheon

  DOI：10.1016/j.bmc.2016.03.044

  日期：2016.5

  The limitations of established serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake inhibitors necessitate the development of safer and more effective therapeutic agents. Based on the structures of 4-benzylpiperidine carboxamides and trazodone, arylpiperazine–benzylpiperidines with chemical scaffolds different from those of marketed drugs were designed, synthesized, and evaluated

  既定的5-羟色胺（5-羟色胺，5-HT）和去甲肾上腺素（NE）再摄取抑制剂的局限性需要开发更安全，更有效的治疗剂。根据4-苄基哌啶羧酰胺和曲唑酮的结构，设计，合成和评估化学支架与市售药物不同的芳基哌嗪-苄基哌啶，并评估其对神经递质再摄取的抑制活性。大多数合成化合物显示出比5-HT再摄取抑制更大的NE。其活性甚至大于标准药物盐酸文拉法辛。具有三碳连接基的衍生物表现出比具有二碳连接基的衍生物更好的活性。在新合成的化合物中，第2d表现出最强的神经递质再摄取抑制作用（ NE的IC 50 = 0.38μM，5-HT的IC 50 = 1.18μM）。生物学活性数据表明，芳基哌嗪-苄基哌啶具有开发作为治疗神经精神病和神经退行性疾病的新型治疗剂的潜力。
• Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma
  作者：Wesam Ali、Gabriella Spengler、Annamária Kincses、Márta Nové、Cecilia Battistelli、Gniewomir Latacz、Małgorzata Starek、Monika Dąbrowska、Ewelina Honkisz-Orzechowska、Annalisa Romanelli、Manuela Monica Rasile、Ewa Szymańska、Claus Jacob、Clemens Zwergel、Jadwiga Handzlik

  DOI：10.1016/j.ejmech.2020.112435

  日期：2020.8

  terms of design, synthesis, and biological assays, including an insight into cellular mechanisms of anticancer action as well as an ADMET-screening in vitro were performed, followed by in-depth SAR analysis. Among the investigated new phenylselenoether hybrids, four compounds showed significant cytotoxic and anti-proliferative effects, in particular, in resistant cancer cells. Hydantoin derivatives (5–7)

  癌细胞中的多药耐药性（MDR）是成功治疗癌症要考虑的关键方面。P-gp / ABCB1是ABC转运蛋白的成员，参与了主要的肿瘤MDR机制，负责药物和细胞毒性物质的外排。在这里，我们描述了一种具有潜在抗癌活性的有效的含硒ABCB1 MDR外排泵调节剂的发现。对三组硒醚进行了设计，合成和生物学分析方面的全面研究，包括深入了解抗癌作用的细胞机制以及体外ADMET筛选进行了深入的SAR分析。在研究的新的苯基硒醚杂化物中，四种化合物表现出显着的细胞毒性和抗增殖作用，特别是在耐药性癌细胞中。乙内酰脲衍生物（5 – 7）比参考抑制剂维拉帕米（在低10倍的浓度下最高可达2.6倍）调节ABCB1外排泵的效果显着，并且还具有良好的药物相互作用曲线。最好的化合物（6在人的JURKAT T淋巴细胞癌细胞中进一步评估了其对细胞增殖速率的影响。从机制上讲，细胞周期增强剂cyclin D1的表达下降，而单独用化合物6或
• Preparation of piperazine derivatives as 5-HT7 receptor antagonists
  作者：Juhee Yoon、Eun A Yoo、Ji-Yeon Kim、Ae Nim Pae、Hyewhon Rhim、Woo-Kyu Park、Jae Yang Kong、Hea-Young Park Choo

  DOI：10.1016/j.bmc.2008.04.023

  日期：2008.5

  Twenty-four compounds of 4-methoxy-N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] benzene sulfonamides and N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] naphthyl sulfonamides were prepared and evaluated as 5-HT(7) receptor antagonists. Most of the compounds showed the IC(50) values of 12-580nM. Four methyl branched analogues were also obtained, but the activity for methyl branched analogues

  4-甲氧基-N- [3-（4-取代的苯基-哌嗪-1-基）丙基]苯磺酰胺和N- [3-（4-取代的苯基-哌嗪-1-基）丙基]二十四种化合物萘磺酰胺被制备并评估为5-HT（7）受体拮抗剂。大多数化合物的IC（50）值为12-580nM。还获得了四个甲基支链类似物，但是对于甲基支链类似物的活性几乎与其直链同源物相同。在合成的化合物中，3c对5-HT（7）受体具有良好的活性，对5-HT（1a），5-HT（2a），5-HT（2c）和5-HT（6）具有良好的选择性）受体。
• Benzothiazine derivative
  申请人：Suntory Limited

  公开号：US05874429A1

  公开（公告）日：1999-02-23

  Disclosed are benzothiazine derivatives represented by the following formula (I): ##STR1## The benzothiazine derivatives (I) and their salts according to the present invention have strong serotonin-2 blocking action, have excellent selectivity to this action against .alpha..sub.1 blocking action and have high safety. Accordingly, the present invention has made it possible to provide pharmaceuticals making use of antagonistic action against serotonin-2 receptors, for example, therapeutics for various circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.

  以下是翻译结果： 揭示了由以下式(I)表示的苯并噻嗪衍生物：苯并噻嗪衍生物(I)及其盐根据本发明具有强大的5-羟色胺-2阻滞作用，对此作用具有出色的选择性，而对α1阻滞作用具有很高的安全性。因此，本发明使得可以提供利用对5-羟色胺-2受体的拮抗作用的药物，例如，用于各种循环系统疾病的治疗药物，如缺血性心脏病、脑血管障碍和外周循环障碍的治疗药物。
• Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
  申请人：Suntory Limited

  公开号：US06271223B1

  公开（公告）日：2001-08-07

  A pyrrolesulfonamide derivative having the following formula (I): is provided wherein P, A, Y, l, Z1 and Z2 are as described herein, wherein the derivative has strong serotonin-2 receptor antagonistic action, low toxicity and fewer side effects, and its use as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.

  提供具有以下化学式（I）的吡咯磺胺衍生物，其中P、A、Y、l、Z1和Z2如本文所述，该衍生物具有强烈的5-羟色胺-2受体拮抗作用，毒性低且副作用较少，可用作治疗循环系统疾病，如缺血性心脏病、脑血管障碍和外周循环障碍的药物。